SHIELD Portal for Breast Cancer
(SHIELD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new app-based tool, the SHIELD portal, designed to support women with hormone receptor-positive breast cancer undergoing long-term endocrine treatment. The researchers aim to determine if this app can help manage care more effectively. Premenopausal women diagnosed with stage 0-IIIa breast cancer and currently receiving treatment can participate. Participants need a US mobile number and must be able to access their medical records.
As an unphased trial, this study offers a unique opportunity to contribute to innovative care solutions and potentially improve personal treatment management.
What prior data suggests that the SHIELD portal is safe for breast cancer patients?
This trial focuses on the SHIELD portal, a web and mobile app designed to assist breast cancer patients. Limited solid data from past studies exists regarding the app's safety. The trial's "Not Applicable" phase label suggests early testing stages, which may explain the lack of extensive safety information.
Since the SHIELD portal is neither a drug nor a medical device, it is likely considered low-risk. Apps of this nature typically provide information or support and generally do not pose the same safety concerns as new medications or treatments. Participants will primarily use educational content or tracking tools. For further details about the app, participants should contact the trial organizers.12345Why are researchers excited about this trial?
The SHIELD portal is unique because it offers a digital approach to managing breast cancer care, potentially enhancing patient engagement and monitoring. Unlike traditional treatment methods that often require frequent in-person visits, the SHIELD portal allows for virtual assessments, which can be more convenient for patients and provide real-time data to healthcare providers. Researchers are excited about this trial because it could lead to more personalized and efficient care, potentially improving outcomes while reducing the burden on both patients and healthcare systems.
What evidence suggests that the SHIELD portal is effective for breast cancer supportive care?
The SHIELD portal is a new tool tested in this trial to support breast cancer patients. Although specific data on the SHIELD portal's effectiveness for breast cancer is not yet available, similar tools, such as apps, often help manage symptoms and improve quality of life. These tools can remind patients to take medication, track symptoms, and provide helpful information. The goal is to assist patients in following their treatment plans and feeling more in control of their care. While specific effectiveness data for SHIELD is pending, it is designed to support patients during their treatment journey.23467
Who Is on the Research Team?
Ann H Partridge, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Participants use the SHIELD portal for supportive care and complete survey assessments
Follow-up
Participants are monitored for assessment completion and portal access rates
What Are the Treatments Tested in This Trial?
Interventions
- SHIELD portal
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
320 participants will be enrolled and will complete the following: Baseline visit (assessments) either by in-person clinic visit or virtually Follow-Up/Post Baseline (3-month assessments) Medical record review (if necessary)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
Breast Cancer Research Foundation
Collaborator
Citations
Understanding Results | Shield™ for Patients
The Shield test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA.
Long-Term Results of Intraoperative Radiation Therapy for ...
Purpose. To present the long-term results of intraoperative radiation therapy (IORT) for early breast cancer using a nondedicated linear accelerator.
Shield™
Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One ...
Shield for Providers | Shield™ for HCPs
The Shield test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA.
Comparative effectiveness of treatment approaches for ...
Our results suggest similar 8-year overall and disease-free survival for BCT and mastectomy among women with early-stage invasive breast cancer, but our ...
Patient-Reported Outcomes in Metastatic Breast Cancer - PMC
This paper examines how PROs are utilized as endpoints in industry-sponsored metastatic breast cancer clinical trials.
Assays of Genetic Expression in Tumor Tissue as a ...
Laboratory tests have been developed to detect the expression, via messenger RNA, of different genes in breast tumor tissue and combine the results to determine ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.